neuropilin and tolloid like 1Genealiases: BCTL1 · BTCL1
Q-omics provides the consensus-scored NETO1 profile across patient tissues and cancer cell-line models. NETO1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, NETO1 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, NETO1 RNA expression shows 14,054 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, HNSC, and GBM as cancer lineages where NETO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NETO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NETO1 survival associations across molecular data types. NETO1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NETO1 RNA expression–survival associations across cancer types. High NETO1 expression shows unfavorable associations in CESC, KIRP, UCEC and UVM, but favorable associations in KIRC and THCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify CESC as the clearest survival context for NETO1 RNA expression.
This table summarizes NETO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NETO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NETO1 shows higher tumor expression in HNSC, KIRC, LUAD, BRCA, LUSC and THCA. The HNSC box plot shows higher NETO1 RNA expression in tumor versus normal tissue (log2 FC = +0.459, t-test p < 0.001).
This table shows molecular features associated with NETO1 in patient tissues and cancer cell lines. In patient samples, NETO1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NETO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
